...
首页> 外文期刊>Ophthalmology >Injection of tissue plasminogen activator into a branch retinal vein in eyes with central retinal vein occlusion.
【24h】

Injection of tissue plasminogen activator into a branch retinal vein in eyes with central retinal vein occlusion.

机译:将组织纤溶酶原激活剂注射到视网膜中央静脉阻塞的眼睛的视网膜分支静脉中。

获取原文
获取原文并翻译 | 示例
           

摘要

PURPOSE: Central retinal vein occlusion (CRVO) often produces significant and permanent loss of vision in the affected eye. The purpose of this study was to determine if patients with vision loss secondary to CRVO treated with retinal vein cannulation and infusion of tissue plasminogen activator (t-PA) experienced recovery of visual acuity. DESIGN: Prospective, noncomparative, interventional case series. PARTICIPANTS: Thirty eyes of 30 consecutive patients with CRVO underwent the procedure, but two were subsequently excluded. The remaining 28 eyes of 28 patients with CRVO for an average of 4.9 months before intervention (range, 0.25-30 months) and best-corrected visual acuity 20/63 or worse were included in the study. INTERVENTION: All patients underwent pars plana vitrectomy with cannulation and infusion of t-PA into a branch retinal vein. MAIN OUTCOME MEASURES: Change in visual acuity and the development of complications such as vitreous hemorrhage and neovascular glaucoma were monitored. RESULTS: Twenty-two of 28 patients (79%) experienced at least one line of visual improvement during the follow-up period (average, 11.8 months; range, 3-24 months), and the same number had this level of improvement at the last follow-up examination. Fifteen patients (54%) gained 3 or more lines of acuity within 6 months after the procedure, and 14 (50%) had acuity at last follow-up at least 3 lines better than baseline acuity (average, 6.8 lines). Seven patients had postoperative vitreous hemorrhages ranging from 1 week to 11 months after the procedure; two cleared spontaneously. One patient had a postoperative retinal detachment from a peripheral retinal break that was repaired successfully with pneumatic retinopexy. No other serious intraoperative or early postoperative complications were noted. CONCLUSIONS: Vitrectomy with retinal vein cannulation and infusion of t-PA is a relatively safe procedure that may improve vision in eyes with CRVO.
机译:目的:视网膜中央静脉阻塞(CRVO)通常会在患眼中造成明显的永久性视力丧失。这项研究的目的是确定接受视网膜静脉插管和输注组织纤溶酶原激活剂(t-PA)治疗的CRVO继发性视力丧失的患者是否恢复了视力。设计:前瞻性,非比较性,介入性病例系列。参与者:连续30例CRVO患者的30眼接受了该手术,但随后排除了2眼。本研究纳入了28例CRVO患者的其余28眼,平均在干预前4.9个月(范围0.25-30个月),且矫正视力达到20/63或更差。干预:所有患者均接受了平面玻璃体切除术,其中插管并向视网膜分支静脉输注了t-PA。主要观察指标:监测视力的变化以及玻璃体出血和新生血管性青光眼等并发症的发生。结果:28名患者中的22名(79%)在随访期间(平均11.8个月;范围3-24个月)至少经历了一条视线改善,并且相同数量的患者在随访时达到了这一水平最后的随访检查。 15位患者(54%)在手术后6个月内获得了3线或更多的视力,最后一次随访时有14位(50%)的视力比基线视力(平均6.8线)好至少3线。手术后1周至11个月,有7例患者发生了玻璃体出血。两个自发清除。一名患者术后视网膜脱离周围性视网膜裂孔,并通过气压性视网膜手术成功修复。没有发现其他严重的术中或术后早期并发症。结论:玻璃体切除术联合视网膜静脉插管和输注t-PA是一种相对安全的方法,可以改善CRVO眼的视力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号